Skip to content

Efficacy and safety of topical application of hemocoagulase atrox in upper gastrointestinal bleeding due to stress ulcer

Efficacy and safety of topical application of hemocoagulase atrox in upper gastrointestinal bleeding due to stress ulcer

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100050584
Enrollment
Unknown
Registered
2021-08-30
Start date
2016-01-01
Completion date
Unknown
Last updated
2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

stress ulcer

Interventions

Topical HA treatment group:Topical use of HA
Cold-saline control group:Topical use of cold-saline
Blank control group:None

Sponsors

Tianjin Medical University General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Hematemesis or melena for the first time, and the occult blood test of gastric juice was positive; 2. At least one major risk factor for bleeding from stress ulcer present within 24 h. The major risk factors expected to be the cause of considerable physiological stress were major head injury with or without chest, abdomen, solid organ, spinal cord, or limb trauma; sudden cerebrovascular event; and major surgery; 3. Clinical condition requiring NICU hospitalization and clinical condition requiring gastric tube in place for more than 48 h.

Exclusion criteria

Exclusion criteria: 1. Significant risk of swallowing blood; 2. Contraindication to placement of an orogastric tube; 3. GBS score >= 6; 4. Enrollment in another clinical study with an HA component within 7 days prior to enrollment in this study; 5. Known or suspected allergic reaction to HA.

Design outcomes

Primary

MeasureTime frame
vital signs;Risk factor assessment;Creatinine clearance;To detect Hb and HCT in Bleeding time;

Countries

China

Contacts

Public ContactXuejun Yang

Tianjin Medical University General Hospital

lsp839015268@163.com+86 22-60814488

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026